BI 1810631
1479-0009
Phase 2 small_molecule active
Quick answer
BI 1810631 for HER2-mutated or overexpressed/amplified solid tumours is a Phase 2 program (small_molecule) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim International GmbH
- Indication
- HER2-mutated or overexpressed/amplified solid tumours
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active